Previous 10 | Next 10 |
Adlai received National Medical Products Administration approval for phase 3 clinical trials in China SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 31, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered imm...
October 30, 2019 FN Media Group Presents USA News Group Commentary Los Angeles, CA – October 30, 2019 – USA News Group – As October rolled in to welcome the 35 th annual Breast Cancer Awareness Month , hope remains alive as new drugs continue to develop...
Study seeks to confirm predictive and prognostic biomarkers demonstrating pelareorep can expand application of checkpoint inhibitors in HR+-metastatic breast cancer SAN DIEGO, CA and CALGARY, AB and PHILADELPHIA, PA / ACCESSWIRE / October 22, 2019 / Oncolytics Biotech ® Inc. (NASD...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is pleased to announce the appointment of Leonard Kruimer, MBA, CPA, to Oncolytics' B...
Across 13 clinical studies and a broad range of cancers, up to 96 percent of tumor samples tested positive for replicating pelareorep virus after intravenous delivery Pelareorep is the only oncolytic virus with meaningful clinical data demonstrating intravenous delivery to tumor tissue ...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 1, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the acceptance of an abstract highlighting data from the AWARE-1 study t...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that its President and Chief Executive Officer, Matt Coffey, Ph.D., MBA,...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 25, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will have an oral presentation at the 12 th Annual Interna...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will be presenting on the Company's pipeline progress, robust ...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has received a notification letter from The Nasdaq Stock Market...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONCY Stock Symbol:
NASDAQ Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Canada NewsWire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report ove...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Canada NewsWire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast ca...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...